CMN 552 Module 1 Exam Actual Exam 2026/2027 – Complete
Exam-Style Questions with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
Section A: Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old male with major depressive disorder is prescribed oral sertraline 50
mg daily. He also takes omeprazole 20 mg daily for GERD and reports drinking
grapefruit juice every morning. The PMHNP recognizes that these factors may alter
drug absorption. Which statement best describes the primary pharmacokinetic concern
in this scenario?
A. Omeprazole increases gastric pH, which may reduce sertraline dissolution and
absorption, while grapefruit juice inhibits intestinal CYP3A4, increasing sertraline
bioavailability. [CORRECT]
B. Omeprazole induces gastric motility, accelerating sertraline transit time and
increasing its absorption rate.
C. Grapefruit juice enhances sertraline absorption by increasing gastric acid secretion,
thereby improving drug solubility.
D. Both omeprazole and grapefruit juice reduce sertraline absorption by competing for
plasma protein binding sites in the gastrointestinal tract.
Correct Answer: A
Rationale: Omeprazole raises gastric pH, which can reduce dissolution of weakly basic
drugs and alter absorption; grapefruit juice inhibits intestinal CYP3A4 metabolism,
increasing bioavailability of substrates like sertraline. Option B is incorrect because
,omeprazole does not induce motility; Option C is incorrect because grapefruit juice does
not increase gastric acid; Option D confuses absorption with distribution (plasma
protein binding occurs post-absorption).
Q2: A 45-year-old patient with bipolar depression requires rapid symptom control. The
psychiatrist orders intravenous ketamine. The nursing student asks why the oral
formulation was not selected. Which pharmacokinetic principle best explains this
clinical decision?
A. IV administration bypasses absorption entirely, providing 100% bioavailability and
immediate onset of action. [CORRECT]
B. IV administration increases the volume of distribution, allowing the drug to
accumulate in adipose tissue for sustained release.
C. Oral ketamine has higher bioavailability than IV ketamine due to extensive first-pass
metabolism in the liver.
D. IV administration prevents renal excretion, thereby prolonging the drug's half-life and
therapeutic effect.
Correct Answer: A
Rationale: Intravenous administration delivers drug directly into systemic circulation,
bypassing absorption barriers and achieving 100% bioavailability with rapid
onset—critical for acute psychiatric stabilization. Option B confuses Vd with route;
Option C is factually reversed (oral bioavailability is lower due to first-pass); Option D
incorrectly states IV prevents renal excretion.
,Q3: A patient taking oral aripiprazole 15 mg daily has a plasma concentration of 75
ng/mL at steady state. The PMHNP calculates the volume of distribution (Vd) to be
approximately 200 L. Which clinical implication is most accurate regarding this finding?
A. A Vd of 200 L indicates extensive tissue distribution beyond total body water,
suggesting high lipophilicity and potential for drug accumulation in adipose tissue.
[CORRECT]
B. A Vd of 200 L indicates the drug is primarily confined to the plasma compartment
and will be rapidly cleared by the kidneys.
C. A Vd greater than 42 L suggests impaired hepatic metabolism, requiring an
immediate reduction in maintenance dose.
D. A Vd of 200 L indicates poor bioavailability, necessitating a switch to parenteral
administration.
Correct Answer: A
Rationale: Vd = Dose/Plasma Concentration; a Vd > 42 L (total body water) indicates
extensive tissue distribution, characteristic of lipophilic psychotropic drugs like
aripiprazole. Option B incorrectly describes low Vd; Option C confuses Vd with hepatic
impairment; Option D confuses Vd with bioavailability.
Q4: A 72-year-old female with treatment-resistant depression is started on oral
tranylcypromine 30 mg daily. The PMHNP counsels her to avoid foods high in tyramine.
Which pharmacokinetic process explains why dietary tyramine poses a life-threatening
risk with this medication?
, A. Tranylcypromine irreversibly inhibits MAO in the gut wall and liver, preventing
first-pass metabolism of tyramine and allowing systemic absorption that triggers
catecholamine release. [CORRECT]
B. Tranylcypromine competes with tyramine for plasma protein binding, displacing
tyramine and increasing its free fraction in the bloodstream.
C. Tranylcypromine induces CYP2D6 enzymes, accelerating tyramine metabolism and
causing dangerous metabolite accumulation.
D. Tranylcypromine reduces gastric motility, allowing tyramine to remain in the intestine
longer and undergo excessive bacterial conversion to norepinephrine.
Correct Answer: A
Rationale: MAOIs like tranylcypromine inhibit monoamine oxidase in gut and liver
(first-pass sites), preventing degradation of dietary tyramine; unmetabolized tyramine
enters circulation and displaces stored catecholamines, causing hypertensive crisis.
Option B confuses protein binding with enzymatic inhibition; Option C is incorrect
(MAOIs do not induce CYP2D6); Option D describes a non-existent bacterial conversion
mechanism.
Q5: A patient on chronic lithium therapy has developed renal insufficiency (CrCl 30
mL/min). The PMHNP reduces the lithium dose by 50%. Which pharmacokinetic
principle primarily necessitates this adjustment?
A. Lithium is excreted unchanged by the kidneys via glomerular filtration and tubular
secretion; reduced renal clearance prolongs half-life and increases toxicity risk.
[CORRECT]
Exam-Style Questions with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
Section A: Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old male with major depressive disorder is prescribed oral sertraline 50
mg daily. He also takes omeprazole 20 mg daily for GERD and reports drinking
grapefruit juice every morning. The PMHNP recognizes that these factors may alter
drug absorption. Which statement best describes the primary pharmacokinetic concern
in this scenario?
A. Omeprazole increases gastric pH, which may reduce sertraline dissolution and
absorption, while grapefruit juice inhibits intestinal CYP3A4, increasing sertraline
bioavailability. [CORRECT]
B. Omeprazole induces gastric motility, accelerating sertraline transit time and
increasing its absorption rate.
C. Grapefruit juice enhances sertraline absorption by increasing gastric acid secretion,
thereby improving drug solubility.
D. Both omeprazole and grapefruit juice reduce sertraline absorption by competing for
plasma protein binding sites in the gastrointestinal tract.
Correct Answer: A
Rationale: Omeprazole raises gastric pH, which can reduce dissolution of weakly basic
drugs and alter absorption; grapefruit juice inhibits intestinal CYP3A4 metabolism,
increasing bioavailability of substrates like sertraline. Option B is incorrect because
,omeprazole does not induce motility; Option C is incorrect because grapefruit juice does
not increase gastric acid; Option D confuses absorption with distribution (plasma
protein binding occurs post-absorption).
Q2: A 45-year-old patient with bipolar depression requires rapid symptom control. The
psychiatrist orders intravenous ketamine. The nursing student asks why the oral
formulation was not selected. Which pharmacokinetic principle best explains this
clinical decision?
A. IV administration bypasses absorption entirely, providing 100% bioavailability and
immediate onset of action. [CORRECT]
B. IV administration increases the volume of distribution, allowing the drug to
accumulate in adipose tissue for sustained release.
C. Oral ketamine has higher bioavailability than IV ketamine due to extensive first-pass
metabolism in the liver.
D. IV administration prevents renal excretion, thereby prolonging the drug's half-life and
therapeutic effect.
Correct Answer: A
Rationale: Intravenous administration delivers drug directly into systemic circulation,
bypassing absorption barriers and achieving 100% bioavailability with rapid
onset—critical for acute psychiatric stabilization. Option B confuses Vd with route;
Option C is factually reversed (oral bioavailability is lower due to first-pass); Option D
incorrectly states IV prevents renal excretion.
,Q3: A patient taking oral aripiprazole 15 mg daily has a plasma concentration of 75
ng/mL at steady state. The PMHNP calculates the volume of distribution (Vd) to be
approximately 200 L. Which clinical implication is most accurate regarding this finding?
A. A Vd of 200 L indicates extensive tissue distribution beyond total body water,
suggesting high lipophilicity and potential for drug accumulation in adipose tissue.
[CORRECT]
B. A Vd of 200 L indicates the drug is primarily confined to the plasma compartment
and will be rapidly cleared by the kidneys.
C. A Vd greater than 42 L suggests impaired hepatic metabolism, requiring an
immediate reduction in maintenance dose.
D. A Vd of 200 L indicates poor bioavailability, necessitating a switch to parenteral
administration.
Correct Answer: A
Rationale: Vd = Dose/Plasma Concentration; a Vd > 42 L (total body water) indicates
extensive tissue distribution, characteristic of lipophilic psychotropic drugs like
aripiprazole. Option B incorrectly describes low Vd; Option C confuses Vd with hepatic
impairment; Option D confuses Vd with bioavailability.
Q4: A 72-year-old female with treatment-resistant depression is started on oral
tranylcypromine 30 mg daily. The PMHNP counsels her to avoid foods high in tyramine.
Which pharmacokinetic process explains why dietary tyramine poses a life-threatening
risk with this medication?
, A. Tranylcypromine irreversibly inhibits MAO in the gut wall and liver, preventing
first-pass metabolism of tyramine and allowing systemic absorption that triggers
catecholamine release. [CORRECT]
B. Tranylcypromine competes with tyramine for plasma protein binding, displacing
tyramine and increasing its free fraction in the bloodstream.
C. Tranylcypromine induces CYP2D6 enzymes, accelerating tyramine metabolism and
causing dangerous metabolite accumulation.
D. Tranylcypromine reduces gastric motility, allowing tyramine to remain in the intestine
longer and undergo excessive bacterial conversion to norepinephrine.
Correct Answer: A
Rationale: MAOIs like tranylcypromine inhibit monoamine oxidase in gut and liver
(first-pass sites), preventing degradation of dietary tyramine; unmetabolized tyramine
enters circulation and displaces stored catecholamines, causing hypertensive crisis.
Option B confuses protein binding with enzymatic inhibition; Option C is incorrect
(MAOIs do not induce CYP2D6); Option D describes a non-existent bacterial conversion
mechanism.
Q5: A patient on chronic lithium therapy has developed renal insufficiency (CrCl 30
mL/min). The PMHNP reduces the lithium dose by 50%. Which pharmacokinetic
principle primarily necessitates this adjustment?
A. Lithium is excreted unchanged by the kidneys via glomerular filtration and tubular
secretion; reduced renal clearance prolongs half-life and increases toxicity risk.
[CORRECT]
